PubMed · 2714599
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
P Isacs. Pull caudad for the impacted stone.. https://doi.org/10.1016/s0016-5107(89)72732-2
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Explore the source record for details and available documents.
With the development and widespread use of flexible endoscopes, injection sclerotherapy of oesophageal varices has advanced beyond the early stages. Although slightly different techniques and different sclerosants are used, the results are not strikingly different. The cumulative rate of adverse effects is in the range of 20 to 40%, with a procedure-related mortality of around 1 to 2%. Sclerotherapy is the best available treatment for haemostasis of acute oesophageal variceal bleeding. However, as a long-term therapy it is less effective in the prevention of recurrent gastrointestinal bleeding events, since obliteration of all varices often takes several months. Furthermore, extra-oesophageal bleeding is not amenable to sclerotherapy. Thus, if repeated injections fail to prevent recurrent bleeding, other options such as shunt surgery, transection, chronic medical portal decompression with beta-blockers or even liver transplantation should be considered according to the needs of the individual patient. Prophylaxis of first variceal haemorrhage was beneficial in selected patients with a high bleeding risk. It cannot, however, be generally recommended at present.
Several endoscopic modalities have the potential of controlling major, life-threatening ulcer bleeding. Although none of the modalities has emerged to be more efficacious than the other, current evidence favours thermal methods and injection therapy. When successful, the endoscopic methods are equally safe (associated with a risk of perforation less than 2%), although a rebleeding rate of 10-30% is of concern. Endoscopic therapy is in general operator-dependent, and the experience of a team is probably more important than the choice of equipment. Selection of patients for endoscopic therapy should be based on the identification of high-risk patients who tolerate rebleeding or surgery poorly, and high-risk lesions likely to rebleed. Endoscopic therapy for ulcer bleeding is simply a new way of applying surgery. Realizing this, it is difficult to understand why therapeutic endoscopy for bleeding ulcer has not yet been widely adopted by surgeons.